The useful life of an intangible asset determines two things that have significant financial impact: the period over which future cash flows are projected in a valuation (affecting the asset's fair value), and the period over which the asset is amortised on the balance sheet (affecting annual earnings).
An overestimated useful life inflates the asset's fair value by including cash flows that may never materialise. An underestimated useful life depresses the value and front-loads amortisation, reducing reported earnings in the near term. Getting the useful life right is therefore critical to both the accuracy of the purchase price allocation and the quality of subsequent financial reporting.
Useful life is not the same as legal life or economic life. It is the period over which the asset is expected to contribute to the entity's cash flows — which may be shorter than the legal protection period or the asset's theoretical economic existence.
| Type | Definition | Example |
|---|---|---|
| Legal life | Period of legal protection | Patent: 20 years from filing |
| Economic life | Period of economic utility to any owner | Technology: until obsolete |
| Useful life | Period of economic benefit to this entity | Technology: until the entity stops using it |
The useful life cannot exceed the economic life, and the economic life cannot exceed the legal life (for legally protected assets). In practice, the useful life is often shorter than both, because the specific entity may have plans that limit the asset's utilisation period.
A patent has a remaining legal life of 12 years, but the underlying technology is expected to be superseded by newer alternatives within 7 years (economic life). The acquiring company plans to transition to a different technology platform within 5 years (useful life). For valuation purposes, the useful life is 5 years — the period over which the patent will actually generate cash flows for this entity.
IAS 38.90 lists the factors to consider when estimating useful life, and ASC 350-30-35-3 gives a similar list under US GAAP:
| Factor | Impact | IAS 38.90 |
|---|---|---|
| Contractual or legal term | Sets maximum life for contract-based assets | (g) |
| Expected usage pattern | Declining usage suggests shorter life | (a) |
| Typical product life cycles | Public estimates for similar assets are evidence | (b) |
| Technical obsolescence | Faster innovation = shorter life | (c) |
| Commercial obsolescence | Market shifts can shorten useful life | (c) |
| Stability of the industry | Volatile industries = shorter asset lives | (d) |
| Expected actions of competitors | Competitive pressure accelerates obsolescence | (e) |
| Maintenance investment required | The life assumes the entity can and will spend what is needed to keep the benefits flowing | (f) |
| Relationship to other assets | Life may be limited by associated assets | (h) |
An asset that arises from contractual or other legal rights cannot have a useful life longer than the period of those rights, although it may be shorter (IAS 38.94); in practice the useful life is the shorter of the economic and the legal period (IAS 38.95). A renewal period counts only where there is evidence the entity will renew without significant cost. IAS 38.96 sets out that evidence:
| Evidence required (IAS 38.96) | Example |
|---|---|
| The rights will be renewed, including any third-party consent needed | A licensor has renewed on standard terms for every past term |
| Any conditions for renewal will be met | Regulatory conditions of an operating licence are being complied with |
| The cost of renewal is not significant compared with the benefits | A registration fee, not a renegotiated price |
If the cost of renewing is significant, the renewal is in substance the acquisition of a new intangible asset, and the original asset's life ends at the current expiry date (IAS 38.96). Useful life and amortisation method are reviewed at least at each financial year end (IAS 38.104).
| Factor | Impact |
|---|---|
| Entity's planned use of the asset | Strategic plans may limit utilisation |
| Expected disposal or abandonment | Planned transitions shorten useful life |
| Integration plans | Merging with existing systems may extend or shorten life |
| Management track record | History of technology refresh cycles |
| Market position | Market leaders can extend asset lives through dominance |
Model the expected customer attrition curve and determine the point at which the surviving customer base no longer generates material cash flows. The useful life is typically defined as the period capturing 90-95% of total projected cash flows.
Assess the innovation cycle in the relevant industry, the maintenance investment required to keep the technology current, and the expected timeline for replacement technologies to emerge.
Start with the contractual term, then assess the probability and expected duration of renewals based on historical data and market practice.
Review useful lives assigned to similar assets in comparable PPA transactions. Industry databases and published deal summaries provide benchmarks.
| Asset Type | Typical Range | Key Driver |
|---|---|---|
| Customer relationships (SaaS) | 7-15 years | Net revenue retention, attrition rate |
| Customer relationships (traditional) | 5-12 years | Contract renewal rates |
| Trade names (established) | 10-25 years or indefinite | Brand strength, market position |
| Technology (software) | 3-7 years | Innovation cycle, obsolescence |
| Technology (industrial) | 5-15 years | Industry stability |
| Patents | Remaining legal term | Up to 20 years |
| Non-compete agreements | Contractual term | Typically 2-5 years |
| In-process R&D | Indefinite until complete | Then finite life assigned |
| Order backlog | Fulfilment period | Typically 6-24 months |
| Favourable contracts | Remaining contract term | No renewal assumed |
Under IAS 38, an intangible asset has an indefinite useful life if there is no foreseeable limit to the period over which it is expected to generate net cash inflows. This does not mean infinite — it means that no expiry can be predicted. Indefinite-life assets are not amortised but are tested for impairment annually.
The indefinite life classification requires strong evidence. Auditors will challenge an indefinite life assertion unless the entity can demonstrate that the asset will continue generating cash flows without foreseeable decline. Historical performance, competitive position, and absence of obsolescence risk must all support the classification. When in doubt, assign a finite life.
Once the useful life is determined, the next question is the pattern of amortisation. IAS 38 requires the amortisation method to reflect the pattern in which the asset's economic benefits are consumed:
| Pattern | When Appropriate | Example |
|---|---|---|
| Straight-line | Benefits consumed evenly | Trade names, licences |
| Accelerated | Benefits front-loaded | Technology (high early revenue, declining over time) |
| Revenue-based | Benefits proportional to revenue | Rare under IAS 38 (see note); used under US GAAP for some customer relationships |
Under IAS 38, a revenue-based amortisation method is presumed inappropriate (IAS 38.98A, added in 2014). The presumption is rebutted only where the asset is expressed as a measure of revenue, such as a licence that ends once a specified revenue level is reached, or where revenue and the consumption of the asset's benefits are highly correlated (IAS 38.98A-98C). US GAAP has no equivalent presumption: ASC 350 requires a method that reflects the pattern in which the benefits are consumed.
The Weighted Average Remaining Useful Life (WARUL) provides a useful aggregate cross-check. It is the weighted average of the useful lives of all identified intangible assets, with each asset weighted by its fair value:
WARUL = Sum of (Fair Value_i / Total Intangible Value) x Useful Life_i
A WARUL that is significantly shorter or longer than expected for the industry may indicate that individual useful life estimates need revisiting. For technology acquisitions, a WARUL of 6-10 years is typical; for pharmaceutical acquisitions, 10-15 years is more common.
Useful life estimation requires a combination of analytical methods, industry knowledge, and professional judgement. Start with the legal and contractual boundaries, narrow to economic life based on obsolescence and competition, and further narrow to the entity-specific useful life based on management's plans. Document the rationale thoroughly — this is an area of frequent audit challenge. The Opagio Calculator models useful life scenarios and shows the valuation impact of different life assumptions. Test your useful life assumptions.
Ivan Gowan is the Founder and CEO of Opagio. His 25 years in fintech — including managing technology platforms through multiple upgrade cycles at IG Group — provides practical understanding of how technology useful lives play out in practice. Meet the team.
Estimate the value of your intangible assets using industry-standard methods like Relief from Royalty, MPEEM, and With & Without.
A practical guide to software capitalisation under IAS 38 and ASC 350-40, plus valuation methods for software as an intangible asset. Covers when to capitalise, how to value, and common mistakes in software asset accounting.
Read more →
IAS 38 measures intangible assets at cost. Valuation enters through IFRS 3, IAS 36 and IFRS 13. When each standard asks for a value, on what basis, and which method fits each kind of asset.
Read more →
How buyers assess and price AI capability in acquisitions — and how sellers should position AI assets for maximum exit value.
Read more →Get the latest insights on intangible asset growth and productivity delivered to your inbox.
Take the free intangible asset assessment to see where your business stands across Opagio 12.